Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masayoshi Harigai

Showing results (11-20 of 309) with videos related to

Pageof 31
Sort By:
Drugs & Aging|February 3, 2016
Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic DrugsTakahiko Sugihara, Masayoshi Harigai
Drugs|July 19, 2020
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?Masayoshi Harigai, Suguru Honda
The Journal of Rheumatology|January 17, 2012
Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group studyMasayoshi Harigai, Yoshiya Tanaka, Shingo Maisawa, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|February 4, 2022
MPO-ANCA positive interstitial pneumonia: Current knowledge and future perspectivesMasashi Bando, Sakae Homma, Masayoshi Harigai
International Journal of Rheumatic Diseases|July 1, 2025
Comparison of Outcomes Between Protocolized Tacrolimus-Based and Non-Protocolized Ciclosporin-Based Triple-Combination Therapy in Interstitial Lung Disease With Anti-MDA5-Positive Dermatomyositis: A Single-Center Retrospective Cohort StudyRisa Yamada, Masayoshi Harigai, Yasuhiro Katsumata
Arthritis Research & Therapy|June 10, 2022
Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort studyRyoko Sakai, Eiichi Tanaka, Masako Majima, et al.
Modern Rheumatology|April 5, 2021
Geographic variations in rheumatoid arthritis treatment in Japan: A nationwide retrospective study using the national database of health insurance claims and specific health checkups of JapanAyako Nakajima, Ryoko Sakai, Eisuke Inoue, et al.
Frontiers in Medicine|September 1, 2022
Advances in Takayasu arteritis: An Asia Pacific perspectiveDebashish Danda, Prathyusha Manikuppam, Xinping Tian, et al.
Lupus|April 16, 2024
Upregulation of PD-1 and its ligands and expansion of T peripheral helper cells in the nephritic kidneys of lupus-prone BXSB-<i>Yaa</i> miceRina Moriyama, Yasuhiro Katsumata, Yuko Okamoto, et al.
RMD Open|June 17, 2024
Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance databaseRyoko Sakai, Eiichi Tanaka, Eisuke Inoue, et al.
Pageof 31

Showing results (11-20 of 309) with videos related to

Sort By:
Pageof 31
Drugs & Aging|February 3, 2016
Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic DrugsTakahiko Sugihara, Masayoshi Harigai
Drugs|July 19, 2020
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?Masayoshi Harigai, Suguru Honda
The Journal of Rheumatology|January 17, 2012
Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group studyMasayoshi Harigai, Yoshiya Tanaka, Shingo Maisawa, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|February 4, 2022
MPO-ANCA positive interstitial pneumonia: Current knowledge and future perspectivesMasashi Bando, Sakae Homma, Masayoshi Harigai
International Journal of Rheumatic Diseases|July 1, 2025
Comparison of Outcomes Between Protocolized Tacrolimus-Based and Non-Protocolized Ciclosporin-Based Triple-Combination Therapy in Interstitial Lung Disease With Anti-MDA5-Positive Dermatomyositis: A Single-Center Retrospective Cohort StudyRisa Yamada, Masayoshi Harigai, Yasuhiro Katsumata
Arthritis Research & Therapy|June 10, 2022
Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort studyRyoko Sakai, Eiichi Tanaka, Masako Majima, et al.
Modern Rheumatology|April 5, 2021
Geographic variations in rheumatoid arthritis treatment in Japan: A nationwide retrospective study using the national database of health insurance claims and specific health checkups of JapanAyako Nakajima, Ryoko Sakai, Eisuke Inoue, et al.
Frontiers in Medicine|September 1, 2022
Advances in Takayasu arteritis: An Asia Pacific perspectiveDebashish Danda, Prathyusha Manikuppam, Xinping Tian, et al.
Lupus|April 16, 2024
Upregulation of PD-1 and its ligands and expansion of T peripheral helper cells in the nephritic kidneys of lupus-prone BXSB-<i>Yaa</i> miceRina Moriyama, Yasuhiro Katsumata, Yuko Okamoto, et al.
RMD Open|June 17, 2024
Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance databaseRyoko Sakai, Eiichi Tanaka, Eisuke Inoue, et al.
Pageof 31